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Abstract
Plasmablastic lymphoma (PBL) clinical descriptions are scarce from sub-Saharan Africa (SSA) where both HIV and
EBV are highly endemic. We identified 12 patients with pathologically confirmed PBL from a prospective cohort in
Lilongwe, Malawi. Median age was 46 (range 26–71), seven (58%) were male, and six (50%) were HIV-positive. Eight
patients were treated with CHOP and four with a modified EPOCH regimen. One-year overall survival was
56% (95% CI 24–79%), without clear differences based on HIV status. PBL occurs in Malawi in HIV-positive and HIV-
negative individuals and can be treated successfully with curative intent, even in a low-resource setting in SSA.
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Introduction
Plasmablastic lymphoma (PBL) is an aggressive
non-Hodgkin lymphoma (NHL) subtype associated with
human immunodeficiency virus (HIV) infection [1], con-
stituting 2% of all HIV-associated lymphomas [2]. Des-
pite strong association with HIV, PBL is also seen in
HIV-negative patients [3, 4]. Epstein-Barr virus (EBV)
increases plasmablasts in blood and lymph nodes in the
presence or absence of HIV, and may play a direct role
in PBL development [5].
Despite high prevalence of HIV infection in
sub-Saharan Africa (SSA), PBL descriptions from the re-
gion are scarce. We describe characteristics, treatment,
and outcomes of PBL patients enrolled in a prospective,
observational cohort in Malawi. This is among the first
detailed clinical descriptions of this unique and aggres-
sive NHL subtype from SSA, where HIV and EBV are
endemic.
Methods
We identified patients with PBL enrolled in the prospect-
ive Kamuzu Central Hospital Lymphoma Study between
May 2013 and May 2017 in Lilongwe, Malawi. PBL diag-
noses were histologically and immunophenotypically
confirmed, and underwent subsequent secondary review
in the United States [6]. All cases were positive for CD138
and negative for CD20 with Ki67 > 90%.
Following diagnosis, all patients underwent standardized
clinical, laboratory, and radiologic assessments as previ-
ously described [7]. Before August 2016, patients were
treated with CHOP (cyclophosphamide 750 mg/m2, doxo-
rubicin 50 mg/m2, vincristine 1.4 mg/m2 day 1, and pred-
nisone 40 mg/m2 days 1–5; 21 day cycles). After August
2016, patients received a modified EPOCH regimen (eto-
poside 50 mg/m2, vincristine 0.4 mg/m2, and doxorubicin
10 mg/m2 days 1–4, prednisone 60 mg/m2 days 1–5, and
cyclophosphamide 750 mg/m2 day 1; 21-day cycles). Be-
cause the local clinical environment does not allow safe
administration of 24-h continuous infusions, 24-h doses
of etoposide, vincristine, and doxorubicin were instead ad-
ministered over 6–8 h on successive days. Hematopoietic
growth factors were not available. All HIV-infected pa-
tients received antiretroviral therapy (ART) concurrent
with chemotherapy.
Cohort characteristics were summarized using simple
descriptive statistics. Patients were followed until death
or administrative censoring on September 30, 2017. Ad-
verse events were reported using National Cancer Insti-
tute Common Terminology Criteria for Adverse Events
version 4.0. Kaplan-Meier methods were used to esti-
mate overall survival (OS). Analyses were conducted
using Stata version 14.1 (College Station, Texas).
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Results
Of 183 adults with pathologically confirmed NHL
during the study period, we identified 12 patients
with PBL (Table 1). Median age was 46 years (range
26–71), seven (58%) were male, and six (50%) were
HIV-positive. Of HIV-positive patients, three were di-
agnosed with HIV prior to PBL diagnosis, and had
been on ART for 6, 10, and 14 months. Among
HIV-positive patients, median CD4 cell count was
147 cell/μL (range 9–460) and three (50%) had sup-
pressed HIV RNA < 400 copies/mL at PBL diagnosis.
Of seven patients whose tumors were tested for
EBV-encoded RNA (EBER) by in situ hybridization,
five (71%) were positive: 3/3 HIV-positive, 2/4
HIV-negative. All patients had a primary site of dis-
ease in the head and neck. Nine (75%) patients had
Ann Arbor stage I/II disease. Median lactate dehydro-
genase was 339 IU/L (range 186–2522 IU/L, upper
limit of normal 250 IU/L).
Eight patients were treated with CHOP for a median
of six cycles (range 1–8). Four patients received the
modified EPOCH regimen for a median of five cycles
(range 2–6). All patients receiving EPOCH and 50% of
CHOP recipients experienced treatment delay due to
grade 3/4 neutropenia and one CHOP recipient experi-
enced delay due to grade 3 anemia. Overall, five (42%)
patients achieved a complete response (CR) after chemo-
therapy [CHOP 2/8 (25%); EPOCH 3/4 (75%)]. Both pa-
tients who achieved CR after CHOP relapsed 4 months
after treatment completion.
As of September 30, 2017, vital status was known for
all patients and median follow-up was 13 months (range
1–35) among patients still alive. One-year OS was 56%
(95% CI 24–79%, Fig. 1). No differences were observed
between HIV-positive patients (1-year OS 67, 95% CI
19–90%) and HIV-negative patients (1-year OS 42, 95%
CI 6–77%, p = 0.53). Of seven deaths, one was due to
neutropenic sepsis and six due to lymphoma
progression.
Discussion
In resource-rich settings, PBL is a rare lymphoma subtype
with poor outcomes [8, 9]. The current National Compre-
hensive Cancer Network guidelines recommend intensive
chemotherapy regimens such as dose-adjusted EPOCH,
hyper-CVAD (cyclophosphamide, vincristine, doxorubicin,
dexamethasone alternating with cytarabine, methotrex-
ate), or CODOX-M/IVAC (cyclophosphamide, vincristine,
doxorubicin, methotrexate alternating with ifosfamide,
etoposide, cytarabine). Consolidative high-dose chemo-
therapy and autologous stem cell rescue in first remission
is also recommended by some [10]. Ongoing studies in
high-income countries are attempting to investigate
anti-myeloma agents (bortezomib, daratumumab, etc.)
added to aggressive NHL chemotherapy regimens to im-
prove outcomes, based on plasmacytic differentiation of
PBL tumor cells [11, 12]. Conversely, other studies have
demonstrated similar or worse results after intensive
chemotherapy regimens compared with CHOP due to ex-
cess treatment-related complications [10, 13].
Table 1 Baseline characteristics of plasmablastic lymphoma patients from the Kamuzu Central Hospital Lymphoma Cohort study
Total (n = 12) HIV+ (n = 6) HIV- (n = 6)
Age, years, median (range) 46 (26–71) 39 (30–60) 53 (26–71)
Male sex, n (%) 7 (58) 2 (33) 5 (83)
Largest tumor location head and neck, n (%) 12 (100) 6 (100) 6 (100)
CNS involvement, n (%) 1 (8) 0 (0) 1 (17)
Bone marrow involvement, n (%) 3 (25) 2 (33) 1 (17)
Largest diameter of mass, cm, median (range) 10 (3–22) 8 (3–15) 11 (10–22)
Ann Arbor stage I/II, n (%) 9 (75) 6 (100) 3 (50)
Performance score≥ 2, n (%) 1 (8) 0 (0) 1 (17)
White blood cells, 103/uL, median (range) 4.6 (2.7–14.9) 11.6 (6.2–12.5) 6.1 (2.7–14.9)
Absolute neutrophils, 103/uL, median (range) 2.74 (0.92–10.6) 2.55 (0.9–4.07) 2.48 (1.3–10.6)
Hemoglobin, g/dL, median (range) 11 (6.2–14.9) 11.6 (6.2–12.5) 10.9 (10.1–14.9)
Platelets, 103/uL, median (range) 206 (103–666) 210 (176–666) 233 (103–458)
Lactate dehydrogenase (LDH), IU/L, median (range)a 338 (186–2522) 328 (240–2522) 226 (186–1803)
CD4 count, cells/μL, median (range) ― 147 (9–460) ―
HIV RNA < 400 copies/mL, n (%) ― 3 (50) ―
EBER expression n (%) 5 (71) 3 (100) 2 (50)
Abbreviations: CNS Central nervous system, EBV Epstein Barr virus, EBER EBV encoded RNA, ECOG PS Eastern oncology cooperative group performance status, HIV
human immunodeficiency virus, LDH lactate dehydrogenase
aLDH normal range = 0–250 IU/L
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Upon first recognition of PBL in Malawi, and due to
supportive care constraints, we initially treated partici-
pants with CHOP resulting in a 25% CR rate, with nearly
all patients dying of progressive disease rather than
treatment-related complications. Given these poor out-
comes, we intensified our approach to a modified
EPOCH regimen adapted as required by clinic infra-
structure, resulting in a 75% CR rate, although follow-up
time for this more recently treated group is limited.
Nevertheless, this experience illustrates that even in a
resource-limited country, sustained investments in cancer
diagnostic and treatment capabilities can lead to recogni-
tion of new tumor types, foundational understanding of
outcomes using standard approaches, and evidence-based
adjustment of therapeutic approaches.
HIV-positive and HIV-negative patients with PBL have
different clinical and pathologic characteristics, including
better response to chemotherapy in HIV-positive patients
[14]. HIV-positive PBL patients are younger, predominantly
male, and have more frequent oral involvement.
HIV-positive PBL cases have significantly higher expression
of CD20, CD56, and EBER compared with HIV-negative
PBL. HIV-positive patients with PBL have also been re-
ported to have better survival than HIV-negative patients
with PBL [14]. We found no difference in OS between
HIV-positive and HIV-negative patients, although our sam-
ple size is small and trends in OS by HIV status were simi-
lar to those described in high-income countries.
Previous studies have indicated that PBL is closely as-
sociated with EBV infection. A metanalysis of PBL cases
demonstrated EBV by in situ hybridization in 75% of
HIV-infected cases and 50% of HIV-uninfected cases [9].
Similarly, our findings confirmed EBV presence in 3/3
HIV-positive cases but only 2/4 HIV-negative cases.
Strengths of our study include its prospective longitu-
dinal nature, no loss to follow-up, standardized treatment,
and pathologic confirmation using immunohistochemistry
and telepathology consultation, all of which are not com-
mon in studies of lymphoproliferative disorders in SSA.
Limitations are small sample size and relatively short
follow-up. Ongoing enrollment and long-term follow-up
will allow better understanding of prognostic factors and
outcomes.
In conclusion, PBL occurs in SSA and may be under-
diagnosed in many settings. Further study is needed to
identify best treatment approaches, but our early experi-
ence suggests treatment intensification might lead to
better outcomes for this population even in highly
resource-limited environments.
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Fig. 1 Overall survival of plasmablastic lymphoma patients in Lilongwe stratified by HIV status. No difference was found between HIV+ and HIV-
patients by log-rank test
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